Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

It comes as new analysis by Asthma and Lung UK found lung diseases were responsible for one in eight emergency hospital ...

ANGLE plc (GB:AGL) has released an update. ANGLE plc’s recent study highlights the potential of dual CTC-DNA and ctDNA analysis in enhancing ...

Treatment options for prostate cancer vary depending on the ... often dismissing their symptoms or feeling embarrassed to ...

Medically reviewed by Marla Anderson, MD Lung cancer causes cancer cells to develop a tumor in the lungs' tissues. Lung ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...